[go: up one dir, main page]

WO2002076480A1 - Extrait de cannabis sativa destine au traitement de la migraine - Google Patents

Extrait de cannabis sativa destine au traitement de la migraine Download PDF

Info

Publication number
WO2002076480A1
WO2002076480A1 PCT/MX2001/000019 MX0100019W WO02076480A1 WO 2002076480 A1 WO2002076480 A1 WO 2002076480A1 MX 0100019 W MX0100019 W MX 0100019W WO 02076480 A1 WO02076480 A1 WO 02076480A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
days
migraine
cures
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MX2001/000019
Other languages
English (en)
Spanish (es)
Inventor
Floripes Medina Gallo
Jaime Tamayo Mora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/MX2001/000019 priority Critical patent/WO2002076480A1/fr
Publication of WO2002076480A1 publication Critical patent/WO2002076480A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Definitions

  • Panicles spikekes with flower and fruit of Canavis sativa L. are required. Panicles can be freshly cut or dried in the sun for three days.
  • the collection of the panicles will be more convenient at sunrise until it reaches the zenith, this is due to the fact that in this time range there is less incidence of small insects, which would reduce the effect of the extract to cure migraine and after The time of the zenith is not conducive to gathering because the wise does not rise in large quantities as in the morning.
  • the extract can be packaged in glass or plastic. This extract should be kept in dark cool places and away from flavorings such as perfumes, camphor or mint. Away from electrical appliances because they reduce healing effects to the extract.
  • the mode of use of the plant extract is to mix 1 liter of the extract in 1 liter of pure cane alcohol. This mixture is what is provided to the patient, to a 10 drops dose every 48 hours for 30 days, then 5 drops are administered every 48 hours for 30 days and finally 2 drops daily for the next thirty days. This is for patients ten years and older.
  • Psychiatric patients and drug addicts do not have stable results due to abandonment of treatment, but the extract is likely to cure if someone is concerned about administering the treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pour obtenir cet extrait de cannabis, il faut ramasser des épis de Cannabis sativa, introduire 100 grammes d'épis dans un litre d'alcool de canne pur et laisser reposer pendant 60 jours. Durant les huit premiers jours, il faut agiter la suspension une fois par jour. A la fin des 60 jours, on obtient un extrait vert foncé qu'il faut soumettre à une filtration pour séparer les résidus végétaux de l'extrait. L'extrait peut être conditionné dans du verre ou du plastique et est utilisé pour traiter les migraines et l'asthme.
PCT/MX2001/000019 2001-03-28 2001-03-28 Extrait de cannabis sativa destine au traitement de la migraine Ceased WO2002076480A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/MX2001/000019 WO2002076480A1 (fr) 2001-03-28 2001-03-28 Extrait de cannabis sativa destine au traitement de la migraine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2001/000019 WO2002076480A1 (fr) 2001-03-28 2001-03-28 Extrait de cannabis sativa destine au traitement de la migraine

Publications (1)

Publication Number Publication Date
WO2002076480A1 true WO2002076480A1 (fr) 2002-10-03

Family

ID=19741766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2001/000019 Ceased WO2002076480A1 (fr) 2001-03-28 2001-03-28 Extrait de cannabis sativa destine au traitement de la migraine

Country Status (1)

Country Link
WO (1) WO2002076480A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2431105A (en) * 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562972A (en) * 1976-01-12 1980-03-19 Yissum Res Dev Co Tetrahydrocannabinols

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562972A (en) * 1976-01-12 1980-03-19 Yissum Res Dev Co Tetrahydrocannabinols

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AMENTA V ET AL: "An epidemiological study on the activity of Cannabis in idiopathic headache", HEADACHE PATHOGENESIS: MONOAMINES, NEUROPEPTIDES, PURINES AND NITRIC OXIDE, vol. 7, 1997, pages 107 - 109, XP002902074 *
EL-MALLAKH R S: "Marijuana and Migraine", HEADACHE, vol. 27, no. 8, September 1987 (1987-09-01), pages 442 - 443, XP002902071 *
HOLLISTER L E: "Health aspects of cannabis", PHARMACOLOGICAL REVIEWS, vol. 38, no. 1, 1986, pages 1 - 20, XP002902072 *
OGBORNE A C ET AL: "Who is using Cannabis as a medicine and why: an exploratory study", JOURNAL OF PSYCHOACTIVE DRUGS, vol. 32, no. 4, October 2000 (2000-10-01) - December 2000 (2000-12-01), pages 435 - 443, XP002902073 *
R STEVENSON: "Cannabis: Proscribed of Prescribed", CHEMISTRY IN BRITAIN, vol. 34, no. 7, July 1998 (1998-07-01), pages 34 - 36, XP002902075 *
RUSSO E: "Cannabis for migraine treatment: the once and future prescription? A historical and scientific review", 1998 INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN, vol. 76, no. 1-2, May 1998 (1998-05-01), pages 3 - 8, XP002902070 *
VOLFE Z ET AL: "Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients", INT. J. CLIN. PHARM. RES., vol. 5, no. 4, 1985, pages 243 - 246, XP002902069 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2431105A (en) * 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US11304393B2 (en) 2016-05-27 2022-04-19 New West Genetics Inc. Industrial hemp cannabis cultivars and seeds with stable cannabinoid profiles

Similar Documents

Publication Publication Date Title
AU725283B2 (en) Bioadhesive pharmaceutical composition for the controlled release of active principles
AP2001002288A0 (en) Methods for treatment of sickle cell anemia.
BR112020006841A2 (pt) formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
US20060062835A1 (en) Multi-disciplinary nicotine craving reduction kit with potentiating homeopathic elements
RU2003128642A (ru) Улучшенная чрескожная терапевтическая система для лечения болезни паркинсона
WO2002041883A3 (fr) Administration, au besoin, d'antidepresseurs tricycliques et d'autres antidepresseurs non inhibiteurs specifiques du recaptage de la serotonine (sri) pour traiter l'ejaculation precoce
WO2005055945A3 (fr) Dispositifs d'administration de medicaments mucoadhesifs et procedes de fabrication et d'utilisation associes
JP2002505296A (ja) Ｎｓａｉｄとともにカノコソウ抽出物、イソ吉草酸またはその誘導体を含む組成物
CA2358054A1 (fr) Utilisation de la cyanocobalamine (vitamine b12) pour le traitement des allergies
CN104940172A (zh) 一种含褪黑素的透皮贴片及其制备方法
WO2002076480A1 (fr) Extrait de cannabis sativa destine au traitement de la migraine
Jacquier et al. Reversible immobilization of free-ranging African lions (Panthera leo) with medetomidine-tiletamine-zolazepam and atipamezole
Guirguis Oral treatment of erectile dysfunction: from herbal remedies to designer drugs
EP1352955A3 (fr) Lymphocytes activés provenant de donneur HLA compatible pour l'utilisation dans la prévention ou la traitement de tumeurs, de maladies infectiveuses ou autoimmunes, dans des méthods de traitement realisées par utilisation de ces lymphocytes; de formule medicinale ayant ces lymphocytes comme constituant principal; dans des méthodes de manufacuture de formule médicinale et la préparation de kit utilisé pour la préparation de formule médicinale
AU649302B2 (en) Tricyclic pyridone derivative
SHEEHY True cholesteatoma: A report of two cases
US20080248130A1 (en) Composition and Method For the Promotion of Hair Growth on a mammal
CN106177089A (zh) 一种治疗腹泻的药物贴片及其制备方法
Koech Cancrum oris in an adult with human immunodeficiency virus infection: case report
Lo Unilateral hypoglossal nerve palsy following the use of the laryngeal mask airway
De Miguel et al. Ankylosing spondylitis and middle ear impairment
US20060029648A1 (en) Stimulant/desensitizer swabs
RU98101617A (ru) Средство для лечения заболеваний пародонта и травматических повреждений слизистой оболочки полости рта "виспосил"
Voigt Notes On The Temperature In A Case Of Advanced Pulmonary Tuberculosis
OKAYAMA et al. Osteogenic Sarcoma of the maxilla: Report of case

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP